Stock Picking - Art Or Science

If there is one Legal way to Become Rich early, it is by Investing in Stocks and Real Estate. In this Blog you will not see general news which are available at numerous sites, instead u will get filtered news and opinions which matter. Many a times some small but important news were overlooked because of simultaneous big event, I try to put all those news in my Blog. The Home Page shows posts of only last 10 days. To see all the posts click on the month in the Archive section.

Friday, February 03, 2006

Stocks To Watch

Savita Chemicals - Savita Chemicals seems to be a wonderful stock. I just came across its third quarter results and I think Savita is a perfect Stalwart as decribed by Peter Lynch.

Savita's estimated Book Value for the YE 2006 is Rs. 205 (Rs. 172 for YE 2005) and estimated EPS is Rs. 38 (Rs. 33.71 for YE 2005), the stock is quoting at Rs. 350.

Savita posted a Net Profit of Rs. 9.39 crores for the QE Dec06 up 17 % from Rs 8.0 crores (YOY). Income from Operations stood at Rs. 189.38 crores up 25.9 % from Rs. 150.40 crores. EPS for QE Dec06 is Rs. 10.72 and for Nine Months it is Rs. 28.34.

I feel at current market price risk reward ratio is in favour of investors.

Sayaji Hotels - Rakesh Jhunjhunwala is rumoured to pick 24 % stake in Sayaji Hotels via preferantial allotment at a price of Rs. 50.00.

Rajshree Sugars - Sugar and Carbon Credits (Sone pe Suhaga). Read This Report.

Hind Sanitary - If there is Boom in Housing and Construction Sector then you can't do without Hind Sanitary.

Ramco Industries - Just get your hands on its Balance Sheet, go to Investments and calculate the Value of its Holdings.

Reliance Energy - If you like Infrastructure plays then keep a close eye on it. Reliance Energy, besides Power, is already in Road Construction on BOLT basis and it is on right track to become a Giant Infrastructure play.

Medicaps - Recommended by Motilal Oswal with a price target of more than Rs. 200

Nelco - Expected to get huge Defence orders, Recommended by Sharekhan with a price target of Rs. 216

Biocon - Have full faith in its R&D Department.

0 Comments:

DISCLAIMER

This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction.

The information contained herein is from publicly available data or other sources believed to be reliable. While I would endeavour to update the information herein on reasonable basis, I am under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent me from doing so. I do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. I do not undertake to advise you as to any change of my views. I may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject me to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. I may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. I may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall I or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.